X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

340B Spotlight: 340B hospitals continue to benefit from consolidation at expense of patients

By Rebecca Davison  |    April 27, 2017
As we’ve noted before, incentives to profit under the 340B program are leading to an uneven playing field for providers and may be shifting care to more expensive and less convenient settings in...   Read More

340B Spotlight: Audit findings show importance of increased oversight of 340B program

By Rebecca Davison  |    February 9, 2017
The 340B Drug Discount Program is an important component of the health care safety net, providing help to vulnerable or uninsured patients. However, with great power comes great responsibility,...   Read More

ICYMI: Data find provider consolidation increases health care costs

By Allyson Funk  |    October 26, 2016
There is a growing body of research on the impact of health care provider consolidation on overall health care spending. In case you missed it, a recent issue brief from the National Institute for...   Read More

340B Spotlight: Trends in shifting site of care

By Rachel Licata  |    September 21, 2016
Research has shown once health care services shift from a provider’s office to a hospital, treatment costs for payers and patients increase. One way hospitals drive this site of care shift is...   Read More

What’s driving insurance premium increases? Hint: It’s not prescription drugs

By Allyson Funk  |    August 2, 2016
A new analysis from Avalere Health looks at 2017 proposed health insurance premium increases. As in 2016, insurers’ own data point to outpatient spending as the largest expected driver of premium...   Read More

Despite rhetoric, new data shows medicines are not primary driver of premium increases

By Karyn Schwartz  |    November 17, 2015
Despite claims from insurers about the impact of medicine costs on premium increases, their own data indicates otherwise.  In fact, just $3.29 of the average $25.26 increase in monthly premiums in...   Read More

340B Spotlight: Health Care Costs Rising from Increase in 340B Hospital Acquisitions of Physician Practices

By Rebecca Davison  |    September 24, 2015
An increasingly popular and alarming trend among 340B hospitals is hurting the integrity of the program and driving up health care costs in the system. Many 340B hospitals are rapidly acquiring...   Read More

340B Mega Guidance

By Allyson Funk  |    September 1, 2015
PhRMA appreciates the Health Resources and Services Administration’s (HRSA) efforts in releasing the 340B mega guidance and is pleased to have an opportunity to comment before the guidance is...   Read More

Who Benefits from the 340B Drug Discount Program?

By Allyson Funk  |    June 10, 2015
The 340B program was created by Congress in 1992 to help vulnerable or uninsured patients gain access to needed prescription medicines, by requiring pharmaceutical manufacturers to provide steep...   Read More

340B Spotlight: New Charity Care Data Shows Most Hospitals with Contract Pharmacies Provide Little Charity Care

By Karyn Schwartz  |    May 21, 2015
New data raises even more questions about how hospitals are using for-profit pharmacies to expand a little known program called 340B. This program was designed to allow qualifying hospitals and...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates